Publications
2023
PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
Mayayo-Peralta I, Gregoricchio S, Schuurman K, Yavuz S, Zaalberg A, Kojic A, Abbott N, Geverts B, Beerthuijzen S, Siefert J, Severson TM, van Baalen M, Hoekman L, Lieftink C, Altelaar M, Beijersbergen RL, Houtsmuller AB, Prekovic S#, Zwart W#. Nucleic Acids Res. 2023 Apr 18:gkad267. doi: 10.1093/nar/gkad267.
#denotes co-corresponding authorship
Racine F, Louandre C, Godin C, Chatelain B, Prekovic S, Zwart W, Galmiche A, Saidak Z. Cancers (Basel). 2023 Feb 28;15(5):1531. doi: 10.3390/cancers15051531.
Severson TM*, Zhu Y*, Prekovic S*, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden M, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A, Wessels L, Corey E, Zwart W, Bergman AM. medRxiv. 2023 Feb 24:2023.02.24.23286403. doi: 10.1101/2023.02.24.23286403. Preprint.
Mammalian life depends on two distinct pathways of DNA damage tolerance
Buoninfante OA*, Spanjaard A*, Pilzecker B*, de Groot D*, Prekovic S$, Song JY, Lieftink C, Ayidah M, Huijbers IJ, Pritchard CEJ, Vivié J, Philipsen S, Pallis J, Zwart W, Beijersbergen R, van den Berk PCM, Jacobs H. Accepted for publication in PNAS.
*denotes shared first authorship / $denotes second authorship
2022
Ribosome impairment regulate intestinal stem cell identity via ZAKɑ activation
Silva J, Alkan F, Ramalho S, Snieckute G, Prekovic S, Garcia AK, Hernandez-Perez S, van der Kammen R, Barnum D, Hoekman L, Altelaar M, Zwart W, Suijkerbuijk SJE, Bekker-Jensen S, Faller WJ. Nat. Commun. 2022. 13(1), 1-12.
2021
Mayayo-Peralta I, Faggion B, Hoekman L, Morris B, Lieftink C, Goldsbrough I, Buluwela L, Post H, Altelaar M, Beijersbergen R, Ali S, Zwart W#, Prekovic S#. Cancers. 2021. 13(24), 6314.
#denotes co-corresponding authorship
The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation
El Kharraz S, Dubois V, Handle F, van Royen ME, Houtsmuller AB, Pavlova E, Atanassova N, Nguyen T, Voet A, Prekovic S, Smeets E, Moris L, Eerlings R, Devlies W, Ohlsson C, Poutanen M, Launonen KM, Helminen L, Palvimo JJ, Libert C, Vanderschueren D, Helsen C, Claessens F. EMBO reports. 2021 Oct 18; e5276
Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TLJ, Murtola T, Granberg KJ, Lamb AD, Ketola K, Mills IG, Attard G, Wang W, Nykter M, Urbanucci A. Nat Commun. 2021. 12(1):1-6.
Prekovic S*#, Schuurman K*, González Manjón A, Buijs M, Mayayo-Peralta I, Wellenstein M, Yavuz S, Barrera A, Monkhorst K, Huber A, Morris B, Lieftink C, Chalkiadaki T, Ferhat A, Faria Da Silva J, Gyorffy B, Hoekman L, van den Broek B, Teunissen H, Debets D, Severson T, Reddy T, Faller W, Beijersbergen R, Jonkers J, Altelaar M, de Visser K, de Wit E, Medema R, and Zwart W#. Nat Commun. 2021 Jul 16;12(1):1-8
*denotes shared first author / #denotes co-corresponding author
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Mayayo-Peralta I, Zwart W#, Prekovic S#. Endocr Relat Cancer. 2021 Apr 1;ERC-20-0489.R1.
#denotes co-corresponding authorship
2020
Kulik M, Bothe M, Kibar G, Fuchs A, Schöne S, Prekovic S, Mayayo-Peralta I, Chung HR, Zwart W, Helsen C, Claessens F, Meijsing SH. Nucleic Acids Res. 2021 Mar 22:gkab185. doi: 10.1093/nar/gkab185.
Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer
Mayayo-Peralta I, Prekovic S, Zwart W. Mol Aspects Med. 2020 Dec 24:100939. doi: 10.1016/j.mam.2020.100939.
Flach KD, Periyasamy M, Jadhav A, Dorjsuren D, Siefert JC, Hickey TE, Opdam M, Patel H, Canisius S, Wilson DM 3rd, Donaldson Collier M, Prekovic S, Nieuwland M, Kluin RJC, Zakharov AV, Wesseling J, Wessels LFA, Linn SC, Tilley WD, Simeonov A, Ali S, Zwart W. Cancer Res. 2020 May 15;80(10):1914-1926. doi: 10.1158/0008-5472.CAN-19-2207. Epub 2020 Mar 19.
2019
Palit SA, Vis D, Stelloo S, Lieftink C, Prekovic S, Bekers E, Hofland I, Šuštić T, Wolters L, Beijersbergen R, Bergman AM, Győrffy B, Wessels LF, Zwart W, van der Heijden MS. Elife. 2019 Dec 19;8:e47430. doi: 10.7554/eLife.47430.
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Handle F*, Prekovic S*, Helsen C, Van den Broeck T, Smeets E, Moris L, Eerlings R, Kharraz SE, Urbanucci A, Mills IG, Joniau S, Attard G, Claessens F. Sci Rep. 2019 Sep 24;9(1):13786. doi: 10.1038/s41598-019-50220-1.
*denotes shared first authorship
Korkmaz G, Manber Z, Lopes R, Prekovic S, Schuurman K, Kim Y, Teunissen H, Flach K, Wit E, Galli GG, Zwart W, Elkon R, Agami R. Nucleic Acids Res. 2019 Oct 10;47(18):9557-9572. doi: 10.1093/nar/gkz675.
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau CS, Vrijland K, Drenth AP, de Korte-Grimmerink R, Schut E, van der Heijden I, Zwart W, Wessels LFA, Schumacher TN, Jonkers J, de Visser KE. Nature. 2019 Aug;572(7770):538-542. doi: 10.1038/s41586-019-1450-6. Epub 2019 Jul 31.
Identification of mineralocorticoid receptor target genes in the mouse hippocampus
van Weert LTCM, Buurstede JC, Sips HCM, Vettorazzi S, Mol IM, Hartmann J, Prekovic S, Zwart W, Schmidt MV, Roozendaal B, Tuckermann JP, Sarabdjitsingh RA, Meijer OC. J Neuroendocrinol. 2019 Aug;31(8):e12735. doi: 10.1111/jne.12735. Epub 2019 Jun 14.
2018
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S. Endocr Relat Cancer. 2018 Oct 31;26(1):R31-R52. doi: 10.1530/ERC-18-0289.
Molecular underpinnings of enzalutamide resistance
Prekovic S#, van den Broeck T, Linder S, van Royen ME, Houtsmuller AB, Handle F, Joniau S, Zwart W, Claessens F#. Endocr Relat Cancer. 2018 Nov 1;25(11):R545–R557. doi: 10.1530/ERC-17-0136.
#denotes co-corresponding authorship
2017
Prekovic S#, Van den Broeck T, Moris L, Smeets E, Claessens F, Joniau S, Helsen C, Attard G. Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):56-63. doi: 10.1016/j.mce.2017.08.020. Epub 2017 Sep 4.
#denotes corresponding authorship
The role of TET-mediated DNA hydroxymethylation in prostate cancer
Smeets E, Lynch AG, Prekovic S, Van den Broeck T, Moris L, Helsen C, Joniau S, Claessens F, Massie CE. Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):41-55. doi: 10.1016/j.mce.2017.08.021. Epub 2017 Sep 1.
Structure of the homodimeric androgen receptor ligand-binding domain
Nadal M*, Prekovic S*, Gallastegui N*, Helsen C, Abella M, Zielinska K, Gay M, Vilaseca M, Taulès M, Houtsmuller AB, van Royen ME, Claessens F, Fuentes-Prior P, Estébanez-Perpiñá E. Nat Commun. 2017 Feb 6;8:14388. doi: 10.1038/ncomms14388.
*denotes shared first authorship
2016
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Prekovic S, van Royen ME, Voet AR, Geverts B, Houtman R, Melchers D, Zhang KY, Van den Broeck T, Smeets E, Spans L, Houtsmuller AB, Joniau S, Claessens F, Helsen C. Mol Cancer Ther. 2016 Jul;15(7):1702-12. doi: 10.1158/1535-7163.MCT-15-0892. Epub 2016 May 16.
Spans L, Van den Broeck T, Smeets E, Prekovic S, Thienpont B, Lambrechts D, Karnes RJ, Erho N, Alshalalfa M, Davicioni E, Helsen C, Gevaert T, Tosco L, Haustermans K, Lerut E, Joniau S, Claessens F. Oncotarget. 2016 Apr 26;7(17):24326-38. doi: 10.18632/oncotarget.8220.
Prekovic S*#, Đurđević DF*, Csifcsák G, Šveljo O, Stojković O, Janković M, Koprivšek K, Covill LE, Lučić M, Van den Broeck T, Helsen C, Ceroni F, Claessens F, Newbury DF#. Sci Rep. 2016 Feb 3;6:20369. doi: 10.1038/srep20369.
*denotes shared first authorship / #denotes co-corresponding authorship
2014
Emerging mechanisms of enzalutamide resistance in prostate cancer
Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, Joniau S. Nat Rev Urol. 2014 Dec;11(12):712-6. doi: 10.1038/nrurol.2014.243. Epub 2014 Sep 16.
Obesity and prostate cancer research
Van den Broeck T, Tosco L, Prekovic S, Joniau S. Cent European J Urol. 2014;66(4):428-9. doi: 10.5173/ceju.2013.04.art8.
Van den Broeck T, Joniau S, Clinckemalie L, Helsen C, Prekovic S, Spans L, Tosco L, Van Poppel H, Claessens F. Biomed Res Int. 2014;2014:627510. doi: 10.1155/2014/627510. Epub 2014 Feb 19.
Androgen receptor antagonists for prostate cancer therapy.
Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F. Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 Mar 17.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines
Spans L, Helsen C, Clinckemalie L, Van den Broeck T, Prekovic S, Joniau S, Lerut E, Claessens F. PLoS One. 2014 Feb 28;9(2): e90002. doi: 10.1371/journal.pone.0090002. eCollection 2014.
Nikolić ZZ, Branković AS, Savić-Pavićević DL, Preković SM, Vukotić VD, Cerović SJ, Filipović NN, Tomović SM, Romac SP, Brajušković GN. Clin Transl Sci. 2014 Aug;7(4):307-13. doi: 10.1111/cts.12130. Epub 2014 Jan 14.